{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:34:41Z","timestamp":1745469281523,"version":"3.40.4"},"reference-count":14,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Princ Pract"],"published-print":{"date-parts":[[2013]]},"abstract":"<b><i>Objective:<\/i><\/b> To compare blood pressure (BP) control in patients receiving irbesartan\/hydrochlorothiazide (HCTZ) and valsartan\/HCTZ at a tertiary care university hospital in Oman. <b><i>Subjects and Methods:<\/i><\/b> This was a retrospective observational study, where 232 patients' medical records were reviewed during a 3-month period, July to September 2010, at Sultan Qaboos University Hospital in Oman. BP readings of the previous 6 months were also retrieved from the electronic medical records. Analyses were conducted using univariate statistical techniques. <b><i>Results:<\/i><\/b> The mean age of the cohort was 58 \u00b1 11 years (range: 21-88). Sixty-nine (30%) patients were on the irbesartan\/HCTZ combination (150\/12.5 mg) and 163 (70%) were on the valsartan\/HCTZ combination. The patients on the valsartan\/HCTZ combination were divided into two subgroups: 117 (72%) received 160\/12.5 mg and 46 (28%) 80\/12.5 mg. Diabetic patients (43\/69, 62%, vs. 61\/163, 37%, p < 0.001) and those with diabetic nephropathy (8\/69, 12%, vs. 7\/163, 4%, p = 0.039) were prescribed more often irbesartan\/HCTZ than valsartan\/HCTZ. In comparison to the valsartan\/HCTZ cohort, the irbesartan\/HCTZ group was associated with significant reductions in both systolic BP (SBP; -9 vs. -2 mm Hg; p = 0.021) and diastolic BP (DBP; -5 vs. 0 mm Hg; p = 0.022). BP reductions were noted more in diabetics than nondiabetics with the irbesartan\/HCTZ patients associated with significant reductions in both SBP (-12 vs. 5.1 mm Hg; p < 0.001) and DBP (-6.4 vs. 1.9 mm Hg; p = 0.001). <b><i>Conclusions:<\/i><\/b> The irbesartan\/HCTZ combination was associated with significant reductions in both SBP and DBP when compared with the valsartan\/HCTZ combination. Specifically, the reductions were noted more in diabetics than nondiabetics.<\/jats:p>","DOI":"10.1159\/000345389","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T14:33:50Z","timestamp":1355409230000},"page":"265-269","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Irbesartan\/ Hydrochlorothiazide and Valsartan\/Hydrochlorothiazide Combination in Lowering Blood Pressure: A Retrospective Observational Study in Oman"],"prefix":"10.1159","volume":"22","author":[{"given":"K.A.","family":"Al Balushi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.Q.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Al-Zakwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17741-1"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2005.04769.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S8062"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90129-4"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2165\/11319460-000000000-00000"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868110-00008"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/10641963.2010.496509"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2005.06.009"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-S012"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000157284"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(00)90005-5"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/00126097-200204000-00008"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02028.x"}],"container-title":["Medical Principles and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/345389","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/345389","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/345389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:35:07Z","timestamp":1745433307000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000345389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,1]]},"published-print":{"date-parts":[[2013,4,2]]}},"URL":"https:\/\/doi.org\/10.1159\/000345389","archive":["Portico"],"relation":{},"ISSN":["1011-7571","1423-0151"],"issn-type":[{"type":"print","value":"1011-7571"},{"type":"electronic","value":"1423-0151"}],"subject":[],"published":{"date-parts":[[2012,12,12]]}}}